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TMUse of Skype sessions with top cancer trial physicians to bring
Interprofessional Education (IPE) into a didactic oncology course
Delilah Navarro, MS, Inder Sehgal, DVM, PhD*
Marshall University School of Pharmacy, Huntington, WVAbstractObjective: To incorporate meaningful Interprofessional Education (IPE) into a core didactic oncology course by bringing into
the classroom a series of cancer specialist physicians, from around the United States, who instructed from and discussed their
own clinical trials.
Methods: The instructor recruited physicians from selected nationwide cancer centers as well as from more regional
institutions. Prior to each IPE session, students pre-read relevant trials or other materials. At an arranged time, an
approximately 30-minute Skype™ session began which included student questions. Assessments of student learning included
individual examinations and a group trial. Survey data was also collected on student views of interprofessionalism, cancer trial
informatics and the role of pharmacists on trial teams.
Results: Group clinical trials showed substantial student creativity and achievement of new skills in trial design. Essays
indicated that students learned as individuals. Survey data showed that prior to the interprofessional sessions, students felt
uncomfortable discussing trial designs/results with graduates of other health professions. Following the sessions and group trial
assignment, students gained signiﬁcant conﬁdence discussing trials with physicians and felt increased recognition for the
pharmacist’s role in the trial team and increased appreciation for the perspective of trial physicians. Students reported that they
enjoyed the opportunity to talk with top cancer physicians.
Conclusions: Didactic core courses can be modiﬁed to accommodate meaningful interprofessional team education.
Considerable time was required to arrange external Skype™ speakers; however, this IPE oncology exercise was very highly
rated by students indicating that this was preparatory time well-invested.
r 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Interprofessional Education (IPE) between health pro-
fessions occurs when educators and learners from two or
more health professions interact to provide knowledge,
skills, and values to the learner.1 IPE should prepare
students to become a contributing member of an interprofes-
sional team, which includes prescribers.2 Interprofessional
collaboration or contribution to a health care team has
become a recognized objective described by multiple
professional accrediting bodies as an important componentpen access article under the CC BY-NC-ND license
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osteopathic,4 dental,5 veterinary,6 and pharmacy schools.2
Accreditation Council on Pharmaceutical Education
(ACPE) Standard 11 speciﬁes an “Interprofessional team
education,” stating, “The curriculum must include oppor-
tunities for students to learn about, from, and with other
members of the interprofessional healthcare team.”2 How-
ever, several realities can be limiting toward interprofes-
sional team education in general and in pharmacy education
speciﬁcally.7 Although such team education need not be
limited to interactions with other health care professions,
interactions with prescriber professions such as medicine
and dentistry are important collaborations in patient care.
Therefore, IPE with other professional doctoral programs is
often more readily accommodated at Health Science Centers
(HSC).7 IPE exercises can be more challenging to set up at
pharmacy programs lacking HSCs, close proximity to other
professional programs, or those located on a small campus.
This becomes even more difﬁcult if IPE is conducted
through student group mixes from different professional
disciplines. In addition, this student–student interaction can
fall short of professional education since the students, by
deﬁnition, are not yet graduates with experience in their
professional discipline.
Prior to clinical rotations, educational interactions
between experienced professionals, such as prescribers, and
students is often through Introductory Pharmacy Practice
Experiences (IPPEs). Although IPPEs and Advanced Phar-
macy Practice Experiences (APPEs) can result in interprofes-
sional team education, ACPE Standard 11 cites a requirement
for IPE both in practice experiences and throughout the
didactic curriculum. Few published examples show mean-
ingful integration of IPE into the didactic curriculum. The
objective of this instructional exercise was to accomplish
high quality and meaningful IPE within a pharmacy program
lacking a large HSC.
Oncology is a subject that is well suited for interprofes-
sional team education. It involves a team-based effort that
can include physicians (e.g., medical oncologists, surgeons,
and/or radiation oncologists), oncology nurses, physician
assistants, dietitians, oncology social workers,8 as well as
community and oncology pharmacy specialists who practice
in a clinic or hospital setting. Oncology is a part of the
didactic curriculum in all pharmacy schools9 and the vast
majority offer APPEs in oncology; however, these are
usually electives. For most students, didactic exposure to
oncology topics will be the extent of their curricular
experience because APPE experiences typically have very
limited rotation slots, particularly at new programs.9 As a
result, many students will not be able to experience IPE
from oncology team professionals.
Clinical trials are an exciting aspect of oncology that have
the potential to foretell the future of agents and treatment
cohorts. They also combine several fundamental aspects of both
basic and clinical oncology such as mechanisms, pharmacoki-
netics, pharmaceutics, pharmacogenomics, biomarkers, adverseevents, medication monitoring, protocols, and counseling. We
felt an exercise in clinical trials could help reinforce other
didactic instruction within a core oncology course. The principle
investigators of national clinical trials are most often physicians
and often at major cancer centers such as those that the National
Cancer Institute (NCI) has designated comprehensive or clinical.
Because most pharmacy schools are not associated with these
major cancer centers, education on trials by the physician
architects is unavailable to the majority of pharmacy students.
Oncology at pharmacy schools is almost always taught using
traditional lecture-based format with some case and/or small
group discussion.10 In this course, we refashioned the traditional
didactic, in-house pharmacy faculty-based instruction template
by incorporating an exercise with cancer specialist physicians
from around the United States to deliver IPE by discussing their
own clinical trials and the roles that pharmacists play in these
trials.
Future cancer protocols are being deﬁned through
ongoing clinical trials. As Principal Investigators (PIs) or
co-investigators of trials, physicians can provide a unique
perspective on up and coming drug agents, treatment
strategies, and biomarkers in oncology. IPE between top
oncology physicians in the region and in the United States
and pharmacy students opens an avenue for students to
learn directly about the design, execution, and nuances of
cancer clinical trials and future therapeutics. During a series
of approximately 30-minute sessions, physicians taught the
class through Skype™ (Redmond, WA)11 by presenting the
set-up and results of their favorite trials, past or current.
Students had the opportunity to ask direct questions
concerning the trial or any aspect of the expert’s ﬁeld of
oncology.
Through discourse with these physicians and other
information presented in the rest of the oncology section
of the therapeutics course, the speciﬁc learning objectives
were for students to (1) identify rationales and predict
adverse effects of drugs used in individual trials, (2) apply
knowledge to their own basic trial design, (3) individually
demonstrate application of learned knowledge by explaining
in writing in lay terms the rationale and purpose of
experimental uses of cancer therapies, and (4) gain knowl-
edge and conﬁdence interacting with professional col-
leagues including physicians. Objective 1 was assessed
through multiple-choice examinations, objectives 2 and 3
were assessed by evaluation of a group designed trial and
individual essays, and objective 4 was assessed through pre-
and post-session surveys.Methods
Educational environment
The student audience was the third year, sixth-semester
oncology class of 77 students taught during the spring
semester of 2015. This IPE exercise was part of an
integrated therapeutics course. Approximately, three hours
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approximately, 15% was spent on the IPE exercise. The
remainder of the oncology section was integrated pharma-
cology, pathology, epidemiology, clinical pharmacology,
pharmacotherapy, and clinical chemistry/laboratory tests
related to oncology. To arrange an IPE interaction between
the students and cancer trial physicians, the instructor
e-mailed physicians at selected NCI-designated clinical
and comprehensive cancer centers as well as local leaders
in cancer treatment advancements. Selection for initial
e-mails was based on several factors including institutional
ranking in U.S News and World Reports “Best Hospitals for
Adult Cancer,”12 regional proximity to our pharmacy
school, or previous working relationship with the instructor.
The initial contact served to introduce the school and
course, explain the goal of personal instruction from a
physician involved directly in clinical trials, and brieﬂy
outline a plan of appearing via Skype™ to perhaps explain a
promising trial’s goals, costs, and pharmacist involvement.
Of these initial contacts, approximately, 10%–20%
resulted in replies back to the instructor. A follow-up
e-mail then began pursuing options for dates and times,
suggested details such as providing a speciﬁc clinical trial’s
NCI identiﬁcation number for the class to pre-read, and
gave guide points to assist the physicians with their
presentations. These included introducing the trial’s target
population if they spoke about a trial, the current standard
of care, the rationale for agent selection, results, and the role
that pharmacists play in that physician’s trial. Through this
approach, Skype™ sessions were pre-arranged with ten
physicians over an approximately 10-week period. Trials
and/or malignancies covered included leukemia/lymphomas
(parts of two sessions), breast cancers (parts of three
sessions), lung (part of one session), and pancreatic, prostate,
and ovarian (one session each). Also included was a
supportive care clinical trial and a session on chemo-
sensitivity technology for individualized therapy. This
spectrum of malignancies is generally reﬂective of common
cancers covered in current pharmacy school curricula.9
Prior to each IPE session, the instructor assigned the trial
(or in some instances a slide presentation from the physician)
to the class to pre-read. At the arranged time, the Skype™
session began and students could view the presenter through
multiple monitors in the classroom. Questions and discus-
sions occurred through the Skype™ webcam. Further stu-
dent–physician interaction was available through e-mail.
Assessments of student learning
Student learning from the interprofessional interactions
was quantitatively and qualitatively assessed according to
the learning objectives as described previously. Because this
exercise was part of a larger course, assessments did not
exclusively measure beneﬁts gained through IPE.
For the group clinical trial exercise, students applied
their knowledge of trials by playing roles of both physicianand pharmacist in the design of their own, usually phase 3
trial. Students were allowed to self-form groups of up to
seven students based on interest in a particular malignancy.
They were to draw upon their IPE experiences and other
learned oncology therapeutics to deﬁne a trial purpose,
construct primary and secondary objectives, treatment arms,
and explain eligibility criteria—identical to the trial sections
discussed by physicians. The primary reference model
provided was the cancer.gov website, http://www.cancer.
gov/cancertopics/pdq/adulttreatment. As the students drafted
these trials, they sent drafts to the instructor for formative
assessments. Creativity in trial drugs and overall design was
encouraged.
For the mock patient response, students were asked to
respond in writing during an examination period to the
following question: “A patient with a malignancy is
considering enrolling in a clinical trial. They ask you as a
pharmacist for advice about the trial. You look up the trial
on the NCI (Physician Data Query) PDQs site and read it.
Pretend it is the trial your group developed and wrote. Now,
please write down below what you would explain to the
patient in understandable terms of: what a clinical trial is in
general, what the purpose of this trial is, what the primary
objective is, what a possible advantage and possible
disadvantage of joining this trial might be to that patient
(be creative here).” One purpose of this individual essay
was to ensure that individuals within the group could clearly
articulate the group’s project. The essay was evaluated on
clarity of deﬁnition of a clinical trial, purpose, primary
objective(s), explanation of advantages and disadvantage of
their particular trial, and overall translation of terminology
into more understandable language.
In addition, surveys were used to measure student
perception of several oncology and interprofessional-
related outcomes that were developed or enhanced through
the exercise. Informed consent was obtained for surveys and
the questions were determined to be exempt by the Marshall
University Institutional Review Board (IRB). To capture
baseline data, a pre-session survey was distributed to each
student approximately one week prior to the ﬁrst IPE
session. A post-session survey was then distributed to all
students one week following the submission of the group
clinical trial. These surveys contained a series of questions
answered through a Likert scale from strongly agree to
strongly disagree. Likert data were ordinally scaled 1–5 and
evaluated between pre- and post-session groups using the
Mann–Whitney U test (Graph-Pad Prism 6.0). The post-
session survey also asked students to provide written
descriptions of what they gained from the IPE sessions
with physicians and what they would recommend to
improve the learning from these sessions.
Results
Multiple choice examination assessments indicated stu-
dents learned to identify the pharmacology and indications
Table 1
Assessments of student learning
Assessment type Objectives assessed
Skills assessed (Bloom's
taxonomy verbs)
Quantitative value of assessment
(mean%  standard deviation of
student scores, n ¼ 77)
Multiple choice exam Identify rationales of drugs used Structure treatment regimens 86.5  16.9
Multiple choice exam Predict adverse effects Recognize potential adverse
outcomes
85.2  20.2
Group-based clinical
trial
Design clinical trial Construct a new project 92.3  7.5
Written individual essay Explain in lay terms rationale and purpose Interpret a multistep process 91.3  9.5
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reactions to oncology agents and procedures (Table 1).
Clinical trials were evaluated on organization, grammar,
statements of purpose and rationale, trial objectives, study
treatment arms, and eligibility criteria. Evaluation of these
trials showed substantial student learning and achievement
of a new skill in trial research and design. The trials were
creative, and often students came up with imaginary new
targeted small molecule inhibitors. These novel agents
would complement existing protocols and offer improve-
ments in adverse effect proﬁles or cohort patient popula-
tions. The process of constructing trials required students to
integrate the perspectives of both pharmacist and physician.
This integration was likely enhanced by the experience of
direct contact with physicians via videoconference.
Essays were evaluated for clarity in explanations to the
questions posed. Scores indicated that not only had students
worked and learned as a group, but also as individuals.
Students scored strongest in grammar, organization, stating
the general purpose of a trial, and explaining eligibility
criteria. They scored weaker in explaining the rationale of
drugs and objectives because they often were unable to fully
translate drug rationales and goals out of technical and into
less complex terms. The next most frequent weakness was
making an implicit assumption that the trial would improve
care—an error of optimism.Survey data
Student impressions were surveyed before and after the
IPE sessions (Table 2). Prior to the sessions, students
largely felt they could not explain goals, time courses, costs
and selection of drug regimens, nor did most know where to
access professional information on cancer topics or trials.
They also lacked conﬁdence in reaching out to and
discussing trial designs or results with colleagues from
other health professions. Following the sessions and group
trial assignment, all of the opinions of all statements
surveyed had signiﬁcantly shifted toward level values
corresponding to agree or strongly agree. Student responses
post-session also indicated greater appreciation for the role
of the pharmacist in the trial team and for the perspective of
trial oncologists. These pre- to post-session shifts indicatedachievement of learning objectives regarding increased
conﬁdence with their ability to interact with and learn from
professional colleagues including physicians.
A post-session survey also provided the students the
opportunity to comment on what they gained most from the
IPE experience and what was lacking. The majority of
students (79.7%) participated in this commentary. The
beneﬁt students stated they gained most from this interpro-
fessional interaction was the perspective of another health
professional, followed by increased appreciation for the
amount of work in a trial, having the opportunity to have a
one-on-one talk with a top trial research physician in the
United States and a greater awareness of the roles played by
pharmacists in cancer clinical trials. Notably, the most
frequent suggestion for improvement was make no changes
at all, followed by requests for more contact time and
suggestions to improve technical issues with the video-
conferencing technology.Discussion
Health-related professional accreditation bodies have
recognized a value in accustoming their students to function
as part of interprofessional teams and they have called for
their respective curricula to encompass education from, and
interaction with, other members of health teams. ACPE
2016 Standard 13.3 lists that “students gain in-depth
experience in delivering direct patient care as part of an
interprofessional team” as a key element of the APPE
curriculum.2 By their nature, external site locations of
APPEs, as well as many IPPEs, have ready potential for
such interactions. However, Standard 11.1 states that “team
dynamics are introduced, reinforced, and practiced in the
didactic… components of the curriculum.”2
From an instructional standpoint, bringing meaningful
IPE into a didactic course is much more challenging than
APPE or IPPE. Classroom courses are taught largely by
pharmacy school faculty who are often highly specialized in
their respective ﬁelds. In a 2012 survey, Newton et al.
reported most pharmacy schools teach oncology pharmaco-
therapy with board-certiﬁed pharmacist oncology special-
ists. Although some pharmacy schools have used physicians
in a general role,10 our IPE exercise is, to our knowledge,
Table 2
Survey instrument response; upper row pre-session survey (n ¼ 74); lower row post-session survey (n ¼ 69)
Likert item
Strongly
agree Agree Neutral Disagree
Strongly
disagree
I can explain the goals of cancer trial objectives. 4.1 24.3 18.9 36.5 16.2
37.7 56.5 5.8 0.0 0.0
I can explain the time course of a clinical trial. 0.0 20.3 12.2 51.4 16.2
33.3 55.1 11.6 0.0 0.0
I can describe considerations that go into selecting drug regiments in
cancer trials.
0.0 20.3 13.5 40.5 25.7
36.2 52.2 11.6 0.0 0.0
I can predict the budget and funding necessary for a clinical trial. 1.4 5.4 13.5 54.1 25.7
2.9 27.5 42.0 26.1 1.4
I can access professional information about cancer clinical trials. 5.4 37.8 29.7 18.9 8.1
58.0 37.7 4.3 0.0 0.0
I feel I am able to discuss the limitations/beneﬁts of cancer clinical trials
with patients.
0.0 12.2 28.4 31.1 28.4
42.0 43.5 14.5 0.0 0.0
I know sources of information that I can refer non-professionals to for
them to access information about cancer clinical trials.
2.7 16.2 28.4 31.1 21.6
37.7 43.5 14.5 4.3 0.0
I am comfortable locating and reaching out to physicians involved in
cancer trials.
2.7 8.1 21.6 37.8 29.7
33.3 43.5 23.2 0.0 0.0
I am able to discuss clinical trial design with colleagues from other
professions.
0.0 9.5 20.3 41.9 28.4
31.9 50.7 14.5 2.9 0.0
I am able to discuss clinical trial results with colleagues from other
professions.
0.0 14.9 23.0 39.2 23.0
33.3 55.1 11.6 0.0 0.0
I recognize how some pharmacists and cancer researchers collaborate in
cancer trials.
2.7 37.8 23.0 24.3 12.2
58.0 37.7 2.9 1.4 0.0
I have an appreciation for the perspective of Cancer trial physicians. 20.3 40.5 16.2 12.2 10.8
65.2 31.9 2.9 0.0 0.0
Numerical values are percentage (%) of each response.
Post-session survey categorical responses were signiﬁcantly (p o 0.001) different than pre-session survey categorical responses for all statements.
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to instruct on clinical trials.
In this exercise, our goal was to develop an IPE within
the didactic setting to enhance student learning and con-
ﬁdence. We introduced meaningful IPE into a core didactic
oncology course by bringing physicians, who are involved
in cancer clinical trials, brieﬂy into our classroom and
learning from their experiences. This instructional interac-
tion allowed our students to learn and dialog with top
physicians from multiple cancer centers who conduct state-
of-the-art patient-based therapeutics. Students were moti-
vated to pre-read the NCI’s clinical trials pages13 in order to
prepare to ask reasonable questions of physicians. The IPE
experience gave them a unique peek into future cancer
therapies, which are currently being determined through
national clinical trials. These are not opportunities that
would have been generally available to the class through
local IPPE/APPE rotations.
Students also learned to use the NCI site to access
information to design their own trial. Post-session survey
data indicated a dramatic turnabout in their comfort level
explaining and describing aspects of cancer trials and
accessing professional information about cancer clinical trials.
These ﬁndings are similar to the reported enhanced con-
ﬁdence in researching oncology resources gained by students
who used an interactive website in an oncology APPE.14The goal of IPE should be to not just instruct, but to
instruct from a different perspective than could be gained
from pharmacy school instructors; this goal was achieved in
this exercise. The outside perspective of cancer therapy and
adverse effects taught students that, for instance, the skin
rash that accompanies small molecule tyrosine kinase
inhibitors is more likely to be viewed by physicians as a
positive response as a biomarker of efﬁcacy than negatively
as a rash. In addition to gaining insight into how physicians
view their roles, the discussions of trials usually included
description of the speciﬁc roles played by pharmacists in
trials, which was of great relevance to the class. Students
saw that physicians recognize and value the role pharma-
cists can play in cancer experimental treatments. In fact, one
oncologist included their trial’s Oncology Pharmacist in the
videoconference session. Survey results documented enhanced
awareness of interprofessionalism, in that students reported
vastly increased familiarity with collaborations between
physicians and pharmacists in trials.
Some barriers to student learning were encountered
during this IPE experience. While students were at ease
listening to speakers discuss topics, there was a reluctance
among many in the class to speak with videoconferencing
physicians. This hesitancy is not surprising and was, in fact,
supported by the pre-session survey data. Pharmacy stu-
dents are not as comfortable talking to physicians as they
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an even greater intimidation factor with physicians from
outside of the home institution and because they came from
some of the top cancer centers in the United States.
However, as the sessions progressed through the semester,
students developed a greater comfort talking to speakers and
the post-session survey data indicate they experienced a
polar shift in their knowledge, comfort, and mutual per-
spectives necessary for interprofessional discourse. This
may have been the greatest accomplishment of this exercise,
as it may better prepare them to be more conversant in
APPEs, residencies, and practice.
A second barrier from the instructional standpoint was
the difﬁculty and time required to schedule multiple clinical
trial investigators from multiple cancer centers, far outside
of the home university, to videoconference in during a
speciﬁc class period at our school of pharmacy. Most e-mail
requests from the instructor received no reply and the
instructor needed to reach far back into his past training
in cancer for contacts and leads. In addition, the instructor
sent out requests to regional cancer centers and searched for
national trial physicians with a link to this state/region. This
effort was necessary and resulted in a much broader and
more diverse set of opinions than would have been possible
had we recruited speakers from just one institution. Once a
speaker had indicated interest, considerable time from both
the speaker and the instructor went into preparing a time
slot and then further collaborations were necessary to
organize the particular method (trial discussion, slide sets,
etc.) used to instruct during the IPE session. A ﬁnal, but not
unanticipated, barrier was occasional technical difﬁculties
with videoconferencing during the instructional sessions.
These included screen freezes, brown-outs, or complete
losses of signal. It became quickly evident that both the
outside speaker and the instructor should always exchange
phone numbers to use for emergency call backs.
In addition to the stated learning objectives, we also
hoped to use this IPE to bring some name recognition to the
new pharmacy school. Participants each received a signed
“Thank You” note from the class and a class “Marshall
University School of Pharmacy Oncology Course” T-shirt.
A future beneﬁt may also be that our exercise generates
interest in oncology training and the outside contacts made
through the IPE facilitate future residency applications.
Finally, outside of the learning for the students, this IPE
presented a unique opportunity for the instructor to learn
more about cutting-edge biomarkers and near-future ther-
apeutics to use in instruction and research.
Conclusion
This IPE exercise demonstrates that didactic core
courses can be modiﬁed in some selected instances to
accommodate meaningful interprofessional team education.
This type of IPE accomplished our learning objectives as
demonstrated by the increases in multiple quantitative andqualitative student assessment measures. Students indicated
they learned from physicians and during this learning they
gained conﬁdence discussing trial designs and results with
interprofessional colleagues. Considerable time was
required to arrange external video conferenced speakers;
however, the high ratings the course received by students
indicate this was preparatory time well-invested.
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